Low cdc27 and high securin expression predict short survival for breast cancer patients

APMIS

Volumn 121, Issue 10, 2013, Pages 945-953

  Talvinen, Kati ^a   Karra, Henna ^a   Pitkänen, Reino ^b   Ahonen, Ilmari ^a   Nykänen, Marjukka ^b   Lintunen, Minnamaija ^a   Söderström, Mirva ^a   Kuopio, Teijo ^b   Kronqvist, Pauliina ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Aneuploidy; Breast cancer; Cdc27; Cell cycle; Prognosis; Securin

Indexed keywords

BIOLOGICAL MARKER; CDC27 PROTEIN; PROTEIN; SECURIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPHASE; ANEUPLOIDY; APOPTOSIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DNA DAMAGE; DNA REPAIR; FEMALE; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; METAPHASE; MITOSIS INHIBITION; PH; PHASE TRANSITION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ANEUPLOIDY; BREAST CANCER; CDC27; CELL CYCLE; PROGNOSIS; SECURIN;

ADULT; AGED; ANEUPLOIDY; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CELL CYCLE PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884731254     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12110     Document Type: Article

References (38)

1. Desmedt C, Sotiriou C. Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle 2006;5:2198-202.
2. Stevens KN, Wang X, Fredericksen Z, Pankratz VS, Cerhan J, Vachon CM, et al. Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer. Breast Cancer Res Treat 2011;129:617-22.
3. Bannon JH, Mc Gee MM. Understanding the role of aneuploidy in tumorigenesis. Biochem Soc Trans 2009;37(Pt4):910-3.
4. Weaver BA, Cleveland DW. The role of aneuploidy in promoting and suppressing tumors. J Cell Biol 2009;185:935-7.
5. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
6. Sherman ME, Howatt W, Blows FM, Pharoah P, Hewitt SM, Garcia-Closas M. Molecular pathology in epidemiologic studies: a primer on key considerations. Cancer Epidemiol Biomarkers Prev 2010;19:966-72.
7. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;15:262-72.
8. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol 2012;19:39-53.
9. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378:1812-23.
10. Roy D, Arason GA, Chowdhury B, Mitra A, Calaf GM. Profiling of cell cycle genes of breast cells exposed to etodolac. Oncol Rep 2010;23:1383-91.
11. Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008;319:617-20.
12. Zhang WH, Poh A, Fanous AA, Eastman A. DNA damage induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle 2008;7:1668-77.
13. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000;33:261-74.
14. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
15. Lee SJ, Langhans SA. Anaphase-promoting complex/cyclosome protein cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis. BMC Cancer 2012;2:44-54.
16. Peters JM. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 2006;7:644-56.
17. Thornton BR, Toczyski DP. Precise destruction: an emerging picture of the APC. Genes Dev 2006;20:3069-78.
18. Izawa D, Pines J. How APC/C-Cdc20 changes its substrate specificity in mitosis. Nat Cell Biol 2011;13:223-33.
19. Karra H, Pitkänen R, Nykänen M, Talvinen K, Kuopio T, Söderström M, et al. Securin predicts aneuploidy and survival in breast cancer. Histopathology 2012;60:586-96.
20. Talvinen K, Karra H, Hurme S, Nykänen M, Nieminen A, Anttinen J, et al. Securin promotes the identification of favourable outcome in invasive breast cancer. Br J Cancer 2009;101:1005-10.
21. Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, et al. Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Br J Cancer 2008;99:335-40.
22. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
23. Pawar SA, Sarkar TR, Balamurugan K, Sharan S, Wang J, Zhang Y, et al. C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc Natl Acad Sci U S A 2010;107:9210-5.
24. R Development Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2012. ISBN 3-900051-07-0, http://www.R-project.org/
25. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418-22.
26. Hamid T, Malik MT, Kakar SS. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer 2005;4:3.
27. Mu YM, Oba K, Yanase T, Ito T, Ashida K, Goto K, et al. Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21 (WAF1/CIP1). Endocr J 2003;50:771-81.
28. Waizenegger I, Giménez-Abián JF, Wernic D, Peters JM. Regulation of human separase by securin binding and autocleavage. Curr Biol 2002;12:1368-78.
29. Hornig NC, Knowles PP, McDonald NQ, Uhlmann F. The dual mechanism of separase regulation by securing. Curr Biol 2002;12:973-82.
30. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000;355:716-9.
31. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R. Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 2006;15:1569-74.
32. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 2006;43:1267-75.
33. Solbach C, Roller M, Eckerdt F, Peters S, Knecht R. Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:242.
34. Topper LM, Campbell MS, Tugendreich S, Daum JR, Burke DJ, Hieter P, et al. The dephosphorylated form of the anaphase-promoting complex protein cdc27/Apc3 concentrates on kinetochores and chromosome arms in mitosis. Cell Cycle 2002;1:282-92.
35. Dai H. van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005;65:4059-66.
36. Kaestner P, Bastians H. Mitotic drug targets. J Cell Biochem 2010;111:258-65.
37. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, Culine S, et al. The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int 2011;108:1782-6.
38. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med 2010;7:e1000279.